NZ574093A - Pan-cell surface receptor- specific therapeutics - Google Patents

Pan-cell surface receptor- specific therapeutics

Info

Publication number
NZ574093A
NZ574093A NZ574093A NZ57409307A NZ574093A NZ 574093 A NZ574093 A NZ 574093A NZ 574093 A NZ574093 A NZ 574093A NZ 57409307 A NZ57409307 A NZ 57409307A NZ 574093 A NZ574093 A NZ 574093A
Authority
NZ
New Zealand
Prior art keywords
ecd
domain
multimer
polypeptide
receptor
Prior art date
Application number
NZ574093A
Other languages
English (en)
Inventor
H Shepard
Original Assignee
Symphogen As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symphogen As filed Critical Symphogen As
Publication of NZ574093A publication Critical patent/NZ574093A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ574093A 2006-06-12 2007-06-12 Pan-cell surface receptor- specific therapeutics NZ574093A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US81326006P 2006-06-12 2006-06-12
US84854206P 2006-09-29 2006-09-29
US87894107P 2007-01-05 2007-01-05
PCT/US2007/071041 WO2007146959A2 (en) 2006-06-12 2007-06-12 Pan-cell surface receptor- specific therapeutics

Publications (1)

Publication Number Publication Date
NZ574093A true NZ574093A (en) 2011-03-31

Family

ID=38832799

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ574093A NZ574093A (en) 2006-06-12 2007-06-12 Pan-cell surface receptor- specific therapeutics

Country Status (11)

Country Link
US (1) US20100055093A1 (cg-RX-API-DMAC7.html)
EP (1) EP2044115A2 (cg-RX-API-DMAC7.html)
JP (1) JP2009539412A (cg-RX-API-DMAC7.html)
KR (1) KR20090031897A (cg-RX-API-DMAC7.html)
AU (1) AU2007257683A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0713272A2 (cg-RX-API-DMAC7.html)
CA (1) CA2655205A1 (cg-RX-API-DMAC7.html)
IL (1) IL195909A0 (cg-RX-API-DMAC7.html)
NZ (1) NZ574093A (cg-RX-API-DMAC7.html)
SG (1) SG172692A1 (cg-RX-API-DMAC7.html)
WO (1) WO2007146959A2 (cg-RX-API-DMAC7.html)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2010119556A (ru) * 2007-10-16 2011-11-27 Симфоген А/С (Dk) Композиции, содержащие оптимизированные мультимеры her1 и her3, и способы их применения
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
JP2010006705A (ja) * 2008-06-13 2010-01-14 Atlas Antibodies Ab Her2サブセット
EP2346526A2 (en) 2008-09-22 2011-07-27 Massachusetts Institute of Technology Compositions of and methods of using ligand dimers
EP2679238A1 (en) * 2008-10-02 2014-01-01 Celtaxsys, INC. Methods of modulating the negative chemotaxis of immune cells
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
CN102470157B (zh) * 2009-07-28 2016-08-17 里加赛谱有限公司 广谱erbb配体结合分子及其制备和使用方法
US9139825B2 (en) 2009-10-30 2015-09-22 Novartis Ag Universal fibronectin type III bottom-side binding domain libraries
RU2579977C2 (ru) 2009-11-13 2016-04-10 Грифольс Терапьютикс Инк. СОДЕРЖАЩИЕ ФАКТОР ФОН ВИЛЛЕБРАНДА (vWF) ПРЕПАРАТЫ И СПОСОБЫ, НАБОРЫ И ПРИМЕНЕНИЯ, СВЯЗАННЫЕ С НИМИ
ES2519348T3 (es) 2010-02-18 2014-11-06 Genentech, Inc. Antagonistas de neurregulina y uso de los mismos en el tratamiento del cáncer
WO2011119836A1 (en) 2010-03-24 2011-09-29 Massachusetts Institute Of Technology Methods and compositions for cardioprotection and cardioregeneration
AU2011283646B2 (en) 2010-07-30 2015-07-09 Novartis Ag Fibronectin cradle molecules and libraries thereof
ME02637B (me) 2010-08-20 2017-06-20 Novartis Ag Antitela za receptor 3 faktora rasta epiderma (her3)
WO2012047175A1 (en) * 2010-10-05 2012-04-12 Kemijski inštitut Fusion polypeptides comprising tir and dimerization domain for modulation of tlr/innate immunity signaling
WO2012103114A2 (en) * 2011-01-24 2012-08-02 Jason Hill Therapeutic chimeric ligand binding proteins and methods for their use
JP5768147B2 (ja) 2011-02-28 2015-08-26 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 一価抗原結合タンパク質
WO2012116926A1 (en) 2011-02-28 2012-09-07 F. Hoffmann-La Roche Ag Antigen binding proteins
CN102219860B (zh) * 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 FGFR-Fc融合蛋白及其用途
CN102219859B (zh) * 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 拮抗血管新生诱导因子的融合蛋白及其用途
WO2012162418A1 (en) * 2011-05-23 2012-11-29 The University Of North Carolina At Chapel Hill Methods and compositions for heterodimeric targeting ligands
WO2012169822A2 (ko) * 2011-06-10 2012-12-13 강원대학교산학협력단 암세포 증식 억제와 혈관신생 억제를 위한 융합 단백질 및 이를 포함한 항암 조성물
KR101397088B1 (ko) 2011-06-10 2014-05-19 강원대학교산학협력단 암세포 증식 억제와 혈관신생 억제를 위한 융합 단백질 및 이를 포함한 항암 조성물
US20150045540A1 (en) 2011-06-28 2015-02-12 Sea Lane Biotechnologies, Llc Multispecific stacked variable domain binding proteins
JP2013040148A (ja) * 2011-08-19 2013-02-28 Asahi Kasei Corp シアリルオリゴ糖ペプチド固定化ビーズ
ES2670651T3 (es) * 2011-10-04 2018-05-31 Expression Pathology, Inc. Ensayo de SRM/MRM para determinar la proteína ERBB-4 del receptor de tirosina-proteína quinasa (HER4)
US9522951B2 (en) 2011-10-31 2016-12-20 Bristol-Myers Squibb Company Fibronectin binding domains with reduced immunogenicity
CN108341873B (zh) 2011-12-05 2022-03-25 诺华股份有限公司 表皮生长因子受体3(her3)的抗体
EP2788382A2 (en) * 2011-12-05 2014-10-15 Novartis AG Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
WO2013110030A2 (en) 2012-01-19 2013-07-25 Duke University Vaccines against antigens involved in therapy resistance and methods of using same
JP6224077B2 (ja) 2012-04-17 2017-11-01 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 改変された核酸を用いてポリペプチドを発現させるための方法
MX2014014162A (es) 2012-05-24 2015-02-04 Hoffmann La Roche Anticuerpos multiespecificos.
WO2014067642A1 (en) 2012-11-05 2014-05-08 Mab Discovery Gmbh Method for the production of multispecific antibodies
EP2727941A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Method for the production of multispecific antibodies
EP2727943A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Trispecific antibodies against human EGFR, HER2 and HER3
EP2727942A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Bispecific antibodies against human EGFR, HER2, and HER3
CN104755499B (zh) * 2012-11-08 2020-10-02 霍夫曼-拉罗奇有限公司 结合HER3 β-发夹和HER4 β-发夹的抗HER3/HER4抗原结合蛋白
CN104755500B (zh) 2012-11-08 2020-10-02 霍夫曼-拉罗奇有限公司 结合HER3 β-发夹的HER3抗原结合蛋白
SI3016512T1 (sl) * 2013-07-05 2020-07-31 H. Lee Moffitt Cancer Center And Research Institute, Inc. Topni CD33 za zdravljenje mielodisplastičnih sindromov (MDS)
BR112016006929A2 (pt) 2013-10-11 2017-09-19 Hoffmann La Roche Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo
EP3088521A4 (en) * 2013-12-25 2017-08-02 Saga University Method for detecting lung cancer
US20160331853A1 (en) * 2014-01-21 2016-11-17 The Trustees Of Columbia University In The City Of New York Compositions for radiotherapy and uses thereof
KR20160144465A (ko) 2014-05-14 2016-12-16 에프. 호프만-라 로슈 아게 Her3의 베타-헤어핀에 결합하는 항-her3 항체
US20170196953A1 (en) 2014-07-07 2017-07-13 Duke University VACCINES AGAINST AN ONCOGENIC ISOFORM OF HER2 (ErbB2) AND METHODS OF USING THE SAME
CA2954279C (en) 2014-07-07 2023-11-14 Duke University Vaccines against an oncogenic isoform of esr1 and methods of using the same
JP2017528430A (ja) 2014-07-17 2017-09-28 ブライアン ジェイ ツェルニキCZERNIECKI, Brian, J. 免疫に基づく療法のための、免疫原性mhcクラスiiペプチドの同定
EP3316871A4 (en) 2015-06-30 2019-02-20 The Trustees of Columbia University in the City of New York TALKED COMPOSITION AND USES THEREOF
US11253580B2 (en) 2016-01-07 2022-02-22 Duke University Cancer vaccines and methods of delivery
WO2018022929A1 (en) * 2016-07-27 2018-02-01 The Trustees Of Columbia University In The City Of New York Gel-bound compositions for radiotherapy and uses thereof
US11224665B2 (en) 2016-10-05 2022-01-18 Duke University Mitochondrial antiviral signaling (MAVS) protein compositions and methods of using the same
US10487143B2 (en) 2016-10-05 2019-11-26 Duke University Vaccines against HER3 antigens and methods of using the same
CA3049652A1 (en) * 2017-01-10 2018-07-19 Intrexon Corporation Modulating expression of polypeptides via new gene switch expression systems
WO2018200951A1 (en) * 2017-04-28 2018-11-01 Tran David T Multi-targeted multi-valent ligand-drug particles for the treatment and prevention of diseases and conditions
EP3635132A4 (en) * 2017-06-07 2021-05-26 Intrexon Corporation EXPRESSION OF NOVEL CELL MARKERS
WO2019096226A1 (en) * 2017-11-16 2019-05-23 Chengdu Easton Biopharmaceuticals Co., Ltd. Pasylated vegfr/pdgfr fusion proteins and their use in therapy
CN111406071B (zh) * 2017-11-16 2024-01-16 成都硕德药业有限公司 Pas化的vegfr/pdgfr融合蛋白及其在治疗中的用途
EP3723792A2 (en) * 2017-12-11 2020-10-21 Medizinische Universität Wien A method of producing a vaccine composition and uses thereof
AR121035A1 (es) * 2019-04-01 2022-04-13 Lilly Co Eli Compuestos de neuregulina-4 y métodos de uso
JP2022540245A (ja) * 2019-07-11 2022-09-14 ザ クリーヴランド クリニック ファウンデーション モデルに基づくステントの設計及び配置のためのシステム及び方法
US20210315870A1 (en) * 2020-04-10 2021-10-14 Postsurgical Therapeutics, Inc. Combinatorial targeted therapy methods
US12268692B2 (en) 2020-04-10 2025-04-08 Postsurgical Therapeutics, Inc. Combinatorial targeted therapy methods
CA3193273A1 (en) 2020-08-27 2022-03-03 Enosi Therapeutics Corporation Methods and compositions to treat autoimmune diseases and cancer
WO2023168426A1 (en) 2022-03-03 2023-09-07 Enosi Therapeutics Corporation Compositions and cells containing mixtures of oligo-trap fusion proteins (ofps) and uses thereof
WO2024186690A2 (en) 2023-03-03 2024-09-12 Enosi Therapeutics Corporation Oligo-trap fusion proteins (ofps) and uses thereof

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) * 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3630200A (en) * 1969-06-09 1971-12-28 Alza Corp Ocular insert
US3847770A (en) * 1972-04-10 1974-11-12 Continental Can Co Photopolymerizable compositions prepared from beta hydroxy esters and polyitaconates
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
WO1985003357A1 (en) * 1984-01-30 1985-08-01 Icrf Patents Ltd. Improvements relating to growth factors
US4931373A (en) * 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
US4769027A (en) * 1984-08-15 1988-09-06 Burroughs Wellcome Co. Delivery system
US4751180A (en) * 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) * 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4687610A (en) * 1986-04-30 1987-08-18 E. I. Du Pont De Neumours And Company Low crystallinity polyester yarn produced at ultra high spinning speeds
US5401638A (en) * 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US5073543A (en) * 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
IT1229203B (it) * 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) * 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5723286A (en) * 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5635177A (en) * 1992-01-22 1997-06-03 Genentech, Inc. Protein tyrosine kinase agonist antibodies
US5792771A (en) * 1992-11-13 1998-08-11 Sugen, Inc. Quinazoline compounds and compositions thereof for the treatment of disease
US5591767A (en) * 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5354566A (en) * 1993-06-02 1994-10-11 Kraft General Foods, Inc. Preparation of yeast-leavened dough crusts
US5994341A (en) * 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
US5457035A (en) * 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
IT1270594B (it) * 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5731168A (en) * 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5639757A (en) * 1995-05-23 1997-06-17 Pfizer Inc. 4-aminopyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors
ATE486937T1 (de) * 1996-07-12 2010-11-15 Genentech Inc Chimärische heteromultimerische adhesine
US7173005B2 (en) * 1998-09-02 2007-02-06 Antyra Inc. Insulin and IGF-1 receptor agonists and antagonists
US7393823B1 (en) * 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
US7396810B1 (en) * 2000-08-14 2008-07-08 Oregon Health Sciences University Compositions and methods for treating cancer by modulating HER-2 and EGF receptors
US8188231B2 (en) * 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US20050239088A1 (en) * 2003-05-16 2005-10-27 Shepard H M Intron fusion proteins, and methods of identifying and using same
WO2005033133A2 (en) * 2003-10-03 2005-04-14 Compugen Ltd. Polynucleotides encoding erbb-2 polypeptides and kits and methods using same
US20070087406A1 (en) * 2005-05-04 2007-04-19 Pei Jin Isoforms of receptor for advanced glycation end products (RAGE) and methods of identifying and using same

Also Published As

Publication number Publication date
WO2007146959A2 (en) 2007-12-21
KR20090031897A (ko) 2009-03-30
SG172692A1 (en) 2011-07-28
WO2007146959A3 (en) 2008-07-24
AU2007257683A1 (en) 2007-12-21
JP2009539412A (ja) 2009-11-19
CA2655205A1 (en) 2007-12-21
US20100055093A1 (en) 2010-03-04
BRPI0713272A2 (pt) 2017-05-02
IL195909A0 (en) 2011-08-01
EP2044115A2 (en) 2009-04-08

Similar Documents

Publication Publication Date Title
US20100055093A1 (en) Pan-cell surface receptor-specific therapeutics
AU779612C (en) Peptide compounds that bind HER2
EP1544299B1 (en) VEGF receptor chimeras for the treatment of eye disorders characterized by vascular permeability
KR20230029621A (ko) T 세포 억제 단백질을 포함하거나 포함하지 않는 april 및 baff 억제 면역조절 단백질 및 이의 사용 방법
US20070161081A1 (en) Hepatocyte growth factor intron fusion proteins
AU2006320858A1 (en) Methods for production of receptor and ligand isoforms
JPH07508178A (ja) レセプター活性化
US20060286102A1 (en) Cell surface receptor isoforms and methods of identifying and using the same
US20050239088A1 (en) Intron fusion proteins, and methods of identifying and using same
AU2005318086B2 (en) BCMA polypeptides and uses thereof
JP4493854B2 (ja) リガンドの生物学的活性を増強する方法
WO2009052184A2 (en) Compositions comprising optimized her1 and her3 multimers and methods of use thereof
CA2257861A1 (en) Hexameric fusion proteins and uses therefor
JP2000046833A (ja) アッセイ、受容体タンパク質nykおよびリガンド
CN101627053A (zh) 泛细胞表面受体特异的治疗剂
CN113795502B (zh) Cd80变体蛋白及其应用
US20090170769A1 (en) Cell surface receptor isoforms and methods of identifying and using the same
CN102470157B (zh) 广谱erbb配体结合分子及其制备和使用方法
US20250388650A1 (en) OLIGO-TRAP FUSION PROTEINS (OFPs) AND USES THEREOF
WO2023168426A1 (en) Compositions and cells containing mixtures of oligo-trap fusion proteins (ofps) and uses thereof
CA2588221C (en) Modified chimeric polypeptides with improved pharmacokinetic properties
HK1043388B (en) Modified chimeric polypeptides with improved pharmacokinetic properties

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: SYMPHOGEN A/S, DK

Free format text: OLD OWNER(S): RECEPTOR BIOLOGIX INC

S38A Application for proceedings under section 38 (amendment of specification with leave of commissioner)

Free format text: BY WAY OF CORRECTION

PSEA Patent sealed
RENW Renewal (renewal fees accepted)
LAPS Patent lapsed